Organ‐protective effect of angiotensin‐converting enzyme 2 and its effect on the prognosis of COVID‐19
Top Cited Papers
Open Access
- 27 March 2020
- journal article
- review article
- Published by Wiley in Journal of Medical Virology
- Vol. 92 (7), 726-730
- https://doi.org/10.1002/jmv.25785
Abstract
This article reviews the correlation between ACE2 and severe risk factors for COVID‐19 and the possible mechanisms. Angiotensin‐converting enzyme 2 (ACE2) is a crucial component of the renin‐angiotensin system (RAS). The classical RAS ACE‐Ang II‐AT1R regulatory axis and the ACE2‐Ang1‐7‐MasR counter‐regulatory axis play an essential role in maintaining homeostasis in humans. ACE2 is widely distributed in the heart, kidneys, lungs, and testes. ACE2 antagonizes the activation of the classical RAS system and protects against organ damage, protecting against hypertension, diabetes, and cardiovascular disease. Similar to SARS‐CoV, SARS‐CoV‐2 also uses the ACE2 receptor to invade human alveolar epithelial cells. ARDS is a clinical high‐mortality disease, and ACE2 has a protective effect on this type of acute lung injury. Current research shows that the poor prognosis of patients with COVID‐19 is related to factors such as sex (male), age (higher than 60 years), underlying diseases (hypertension, diabetes, and cardiovascular disease), secondary ARDS, and other relevant factors. Because of these protective effects of ACE2 on chronic underlying diseases and ARDS, the development of spike protein‐based vaccine and drugs enhancing ACE2 activity may become one of the most promising approaches for the treatment of COVID‐19 in the future.Keywords
Funding Information
- National Natural Science Foundation of China (81870417)
This publication has 39 references indexed in Scilit:
- Angiotensin-Converting Enzyme 2 Suppresses Pathological Hypertrophy, Myocardial Fibrosis, and Cardiac DysfunctionCirculation, 2010
- Vasoprotective and Atheroprotective Effects of Angiotensin (1-7) in Apolipoprotein E–Deficient MiceArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- The ANG-(1–7)/ACE2/mas axis in the regulation of nephron functionAmerican Journal of Physiology-Renal Physiology, 2010
- Targeting the Degradation of Angiotensin II With Recombinant Angiotensin-Converting Enzyme 2Hypertension, 2010
- Human Recombinant ACE2 Reduces the Progression of Diabetic NephropathyDiabetes, 2009
- ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic miceKidney International, 2007
- Age- and gender-related difference of ACE2 expression in rat lungLife Sciences, 2006
- Characterization of Renal Angiotensin-Converting Enzyme 2 in Diabetic NephropathyHypertension, 2003
- A Human Homolog of Angiotensin-converting EnzymeJournal of Biological Chemistry, 2000
- Haemodynamic and endocrine effects of type 1 angiotensin II receptor blockade in patients with hypoxaemic cor pulmonaleCardiovascular Research, 1997